The short version
5 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Veletri
epoprostenol · EPOPROSTENOL 1.5 mg/10mL · Injection, Powder, Lyophilized, For Solution · Intravenous · Actelion Pharmaceuticals US, Inc.
NDC 66215-0402-01 · 1 VIAL in 1 CARTON / 10 mL in 1 VIAL · NDA · View full market →
One drug, every price
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
ⓘ How this was built
Data sources
- CMS NADAC (pharmacy acquisition, weekly)
- CMS Part B ASP quarterly payment limits
- CMS Maximum Fair Prices (IRA negotiated, NDC-level)
- Medicare Part D Spending by Drug (data.cms.gov, name-matched)
- VA FSS / Big4 federal contract prices (va.gov, twice monthly)
- ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
- California SB-17 WAC filings (list price, per package)
Method
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
- Medicare Part B pays (ASP+6%)$16.92per billing unit (0.5 MG)HCPCS J1325 · Jul 1, 2026
- Part D plans paid (avg)$52.49per dosage unitgross, before rebates — matched by drug name · 2024
- Federal ceiling (Big4)$39.21per unitActelion Pharmaceuticals, U.S. Inc. · Jan 1, 2026
- List price (WAC, as filed)$58.58per packageActelion Pharmaceuticals US, Inc · Jan 29, 2026
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$55.26
Reported to Texas DSHS · 2026 annual filing · Johnson & Johnson Health Care Systems Inc
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicare Part B (ASP)
Payment limit per 0.5 MG
$16.918
HCPCS J1325 · Jul 1, 2026 quarter · typically ASP + 6%
Medicaid spend (2025)
$3.2M
1,250 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- AndersonBrecon Inc.United Stateslabel · pack
- Cayman Pharma s.r.o.Czech Republicapi manufacture
- analysis · label · manufacture · pack
- analysis · label · manufacture · pack
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $2,715.92 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA022260
- TE code
- AP2
- Approval date
- Jun 27, 2008
- Patents / exclusivity
- 4 patents, 0 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| patent | 8318802 | Mar 15, 2027 |
| patent | 8318802 | Mar 15, 2027 |
| patent | 8598227 | Feb 2, 2027 |
| patent | 8598227 | Feb 2, 2027 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of epoprostenol (Injection, Powder, Lyophilized, For Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. | EPOPROSTENOL .5 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
| Actelion Pharmaceuticals US, Inc. | EPOPROSTENOL 1.5 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
| Gland Pharma Limited | EPOPROSTENOL 1.5 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
| Gland Pharma Limited | EPOPROSTENOL .5 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
| Mylan Institutional LLC | EPOPROSTENOL .5 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
| Mylan Institutional LLC | EPOPROSTENOL 1.5 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
| Sun Pharmaceutical Industries, Inc. | EPOPROSTENOL SODIUM .5 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
| Sun Pharmaceutical Industries, Inc. | EPOPROSTENOL SODIUM 1.5 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
| Wasserburger Arzneimittelwerk GmbH | EPOPROSTENOL 1.5 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Veletri — NDC 66215-0402-01," retrieved September 3, 2026, https://drugdashboards.com/drug/66215040201.
Free to cite with attribution — see how the data is put together.